Core Viewpoint - Investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period may have the opportunity to lead a securities fraud lawsuit due to alleged misleading statements regarding the company's drug trials [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx provided investors with overly positive information about the expected results of its Phase III studies for setrusumab (UX 143) in treating Osteogenesis Imperfecta (OI) [5]. - Defendants allegedly made confident statements about setrusumab's ability to reduce fracture rates in OI patients while concealing material adverse facts about the drug's true efficacy and the risks associated with the study protocols [6]. - The lawsuit asserts that these misleading statements led to Ultragenyx securities being purchased at artificially inflated prices, resulting in investor losses when the true information became public [6]. Group 2: Class Action Participation - Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, are encouraged to join the class action lawsuit, with a lead plaintiff deadline set for April 6, 2026 [1][3]. - Participation in the class action does not require any out-of-pocket fees, as compensation is arranged through a contingency fee structure [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][7].

Core Viewpoint - Super Micro Computer, Inc. is facing a securities class action lawsuit due to allegations of a $2.5 billion scheme involving illegal diversion of AI servers to China, resulting in a significant drop in share price by 33.3% [2][9] Company Overview - Super Micro Computer, Inc. is implicated in a legal case that spans from April 30, 2024, to March 19, 2026, with two senior executives named as individual defendants [1][9] Executive Accountability - Charles Liang, CEO and President, is accused of controlling the company's SEC filings and making misleading public statements about AI infrastructure demand while concealing illegal sales [3][5] - David Weigand, CFO, is alleged to have direct responsibility for financial reporting and compliance with U.S. export regulations [4][5] Legal Framework - The lawsuit invokes Section 20(a) of the Securities Exchange Act, which holds individuals liable for violations committed by the company they control [5] - Under the Sarbanes-Oxley Act, both Liang and Weigand certified that the company's SEC filings were accurate, which the lawsuit claims was false due to the illegal activities [5][9] Allegations of Knowledge - The complaint suggests that the individual defendants were aware or recklessly disregarded the fact that revenue growth was significantly driven by illegal server sales [7][9] Class Action Details - The class action lawsuit alleges that Super Micro made materially false and misleading statements, leading to substantial losses for shareholders [9] - Investors are encouraged to gather brokerage records to assess their eligibility for participation in the class action [10][12]

Core Insights - Boston Scientific Corporation (BSX) is facing a securities class action due to allegations of misleading statements regarding its U.S. Electrophysiology segment growth and competitive positioning, which led to significant market capitalization loss [4][8] Institutional Investor Considerations - Institutional investors who held BSX shares from July 23, 2025, to February 3, 2026, may want to evaluate lead plaintiff opportunities in the ongoing class action [1][8] - The stock price of BSX dropped from $91.62 to $75.50 on February 4, 2026, resulting in a single-day loss of $16.12 per share, or 17.6% [2] - Fund managers and fiduciaries are encouraged to assess their exposure and consider recovery options due to concentrated losses in BSX [3][5] Financial Performance and Guidance - The company had raised its full-year 2025 guidance multiple times, projecting approximately 20% reported revenue growth and 15.5% organic revenue growth, along with adjusted EPS of $3.02 to $3.04 as of October 22, 2025 [6] - The complaint claims that these optimistic projections were made despite adverse trends affecting the segment's performance [6] Legal Framework - The class action was filed in the United States District Court for the District of Massachusetts, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [8] - Institutional investors are critical in securities class actions, as their involvement can enhance the efficiency of litigation and ensure that recoveries reflect the full extent of shareholder harm [7]

Core Viewpoint - Apollo Global Management, Inc. is facing a securities class action due to undisclosed communications between senior leadership and Jeffrey Epstein, leading to significant share price declines and potential fiduciary obligations for institutional investors [2][5]. Group 1: Share Price Impact - APO shares fell approximately $5.99 per share after disclosures about undisclosed communications with Epstein, with shares dropping from above $119 to $113.73 [2][4]. - The corrective disclosures occurred in February 2026, resulting in material portfolio losses for institutional holders [4]. Group 2: Legal Context - The lawsuit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, claiming Apollo Global concealed the extent of interactions with Epstein regarding business matters [5]. - The company had previously asserted no business dealings with Epstein in its SEC filings, which were signed with Sarbanes-Oxley certifications, creating a false sense of confidence in management integrity [4]. Group 3: Institutional Investor Role - Institutional investors are encouraged to evaluate lead plaintiff opportunities to maximize recoveries for all class members affected by the alleged securities fraud [6]. - The firm Levi & Korsinsky, LLP offers counsel to institutional investors, emphasizing the importance of fiduciary duties in assessing potential recoveries [7].

Core Viewpoint - Soleno Therapeutics, Inc. is facing a securities class action lawsuit alleging that the company and its officers concealed material safety risks associated with its product DCCR during the class period from March 26, 2025, to November 4, 2025 [2][7]. Group 1: Company Overview - Soleno's sole commercial product, VYKAT XR, was approved by the FDA on March 26, 2025, to treat hyperphagia in individuals with Prader-Willi syndrome [2]. - The lawsuit claims that Soleno made materially misleading statements regarding DCCR's safety profile and commercial viability, while concealing evidence of serious adverse events [5]. Group 2: Legal Proceedings - The U.S. District Court for the Northern District of California has set May 5, 2026, as the deadline for institutional investors to apply for lead plaintiff appointment in the class action [2]. - The action alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of all purchasers of Soleno common stock during the specified class period [7]. Group 3: Institutional Investor Considerations - Institutional investors who acquired SLNO shares during the class period may have fiduciary obligations to evaluate the pursuit of a lead plaintiff role [3]. - The PSLRA favors institutional investors with the largest financial interest in the relief sought by the class, and lead plaintiffs have the authority to select and oversee class counsel [7][8].

Core Viewpoint - ChowChow Cloud International Holdings Limited (NYSE American: CHOW) experienced a significant stock collapse of 84.3% on December 10, 2025, attributed to alleged market manipulation, leading to a call for investors to seek recovery of losses [2][8]. Group 1: Stock Performance and Trading Activity - CHOW shares were initially priced at $4.00 during its IPO on September 16, 2025, and surged to an intraday high of $21.91 on the first trading day, closing at $12.61 [3]. - Following the initial surge, shares fell sharply, closing at $5.01 by September 19, 2025, after the company announced the closing of its IPO with total gross proceeds of $11.96 million [4]. - A second surge occurred on September 30 and October 1, 2025, with shares gaining over 33% despite no company news justifying the increase [5]. - On October 15, 2025, CHOW reached an intraday high of $9.44, but trading volume collapsed the following day, illustrating erratic trading patterns [6]. - A third wave of trading activity occurred from October 23 to 31, 2025, with shares climbing to $10.22 and experiencing a significant increase in trading volume without any company disclosures [7]. Group 2: Allegations of Market Manipulation - The lawsuit alleges that the IPO prospectus omitted known risks of fraudulent promotion and market manipulation targeting CHOW shares [9]. - Throughout the trading period, there were multiple instances of unexplained volume spikes and extreme volatility, with the company failing to address these issues in its communications [9]. - The trading was halted twice on December 10, 2025, due to volatility linked to the alleged market manipulation, resulting in a drastic drop in share value from $11.70 to $1.83 [8]. Group 3: Legal and Recovery Information - Investors who purchased CHOW securities between September 16, 2025, and December 10, 2025, may be entitled to recover damages, with the deadline to apply for lead plaintiff status closing on May 12, 2026 [1][10]. - The firm Levi & Korsinsky has a history of representing shareholders in securities class actions and emphasizes the importance of timely disclosure of material developments to maintain market integrity [11].

Core Viewpoint - The Schall Law Firm is investigating ePlus inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements and failed to disclose important information to investors [2]. Group 1: Investigation Details - The investigation is centered on ePlus's Q3 financial results announced on February 5, 2025, which fell short of consensus estimates, attributed to "digestion" in the networking space and select enterprise customers [2]. - Following the announcement of the disappointing financial results, ePlus's shares experienced a significant decline of 13.1% the next day [2]. Group 2: Investor Participation - Shareholders who have suffered losses are encouraged to participate in the investigation and can contact the Schall Law Firm for more information [3].

Core Viewpoint - Investors in ODDITY Tech Ltd. have the opportunity to lead a securities fraud class action lawsuit due to alleged undisclosed issues affecting the company's financial performance and business model [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that from February 26, 2025, to February 24, 2026, ODDITY Tech Ltd. failed to disclose significant changes that negatively impacted its business [3]. - Key allegations include that an algorithm change by Oddity's largest advertising partner led to advertisements being diverted to lower quality auctions at abnormally high costs, significantly increasing customer acquisition costs [3]. - The complaint claims that these undisclosed issues resulted in the overstatement of the company's operational strength and market position, making previous positive statements materially misleading [3]. Group 2: Participation Information - Investors who suffered losses related to ODDITY Tech Ltd. are encouraged to participate in the ongoing lawsuit, with a lead plaintiff deadline set for May 11, 2026 [2][4]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to learn about their rights regarding the lawsuit [4][5].

Core Viewpoint - Vital Farms, Inc. is facing a class action lawsuit for securities fraud due to misleading statements regarding the impact of delays related to its new enterprise resource planning (ERP) system [4]. Group 1: Lawsuit Details - The Schall Law Firm is leading a class action lawsuit against Vital Farms for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased securities between May 8, 2025, and February 26, 2026, are encouraged to participate in the lawsuit before the deadline of May 26, 2026 [2]. - The lawsuit claims that Vital Farms made false statements about the risks associated with its ERP system, which ultimately led to missed earnings per share [4]. Group 2: Investor Information - The Schall Law Firm specializes in securities class action lawsuits and is representing investors globally [5]. - Investors who suffered losses due to the misleading statements are invited to contact the firm for a free discussion of their rights [3].

Core Viewpoint - The Trip.com Group Limited is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding regulatory risks associated with their monopolistic practices [1][3]. Group 1: Lawsuit Details - The class action lawsuit, titled De Wilde v. Trip.com Group Limited, allows purchasers of Trip.com securities between April 30, 2024, and January 13, 2026, to seek appointment as lead plaintiff by May 11, 2026 [1]. - Allegations include that Trip.com understated regulatory risks due to its monopolistic business activities, which were not disclosed to investors [3]. - A significant event occurred on January 14, 2026, when Bloomberg reported that China was investigating Trip.com for alleged antitrust conduct, leading to a 19% drop in the company's American Depositary Shares over two trading sessions [4]. Group 2: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Trip.com securities during the class period to seek lead plaintiff status, representing the interests of the class [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [5]. Group 3: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history at $7.2 billion [6].